UK’s NICE makes Nivolumab available for head and neck cancer patients
Nivolumab works by binding to certain proteins in cells. This then stimulates the body’s immune system to attack cancerous cells and destroy them. When NICE first reviewed nivolumab,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.